Biofrontera Inc. Common Stock (BFRI)
Stock · NASDAQ · Health Care
$0.8252as of 10/16/2026
Price chart
Active signals
BFRI Signal Track Record
How signals performed across all stocks →What BFRI's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 36 | -2.4% | 44% | September 2, 2026 |
| Bollinger Band Breakdown | 19 | +1.8% | 53% | September 15, 2026 |
| Bollinger Band Breakout | 18 | -13.4% | 28% | August 18, 2026 |
| 200-Day Moving Average TouchActive now | 8 | -1.0% | 50% | October 2, 2026 |
| Any 20-session window (baseline) | -4.2% | 41% |
Computed by MarketWall from daily closing prices since August 16, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About BFRI
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massac…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 84
- Website
- www.biofrontera-us.com/
Fundamentals
- 1-day range
- $0.8215$0.92
- Market cap
- $16.00M
- P/E (trailing)
- —
- P/E (forward)
- 1.91
- EPS (trailing)
- $-0.59
- Dividend yield
- —
- Beta
- 0.91
- Avg. volume
- 545.1K
How Biofrontera Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 19, 2026 · via SEC EDGAR / Finnhub
Forecasts
2 analyst ratings
Biofrontera Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- BFRIBiofrontera Inc. Common Stock$0.822▼ 2.95%Market cap $16.00MP/E —$0.555$1.66
- SKYESkye Bioscience Inc. Common Stock$1.55▼ 2.52%Market cap $16.58MP/E —$1.5$13.28
- CYCNCyclerion Therapeutics Inc. Common Stock$3.36▼ 0.15%Market cap $16.67MP/E —$7.19$59.36
- SCNXScienture Holdings Inc. Common Stock$3.36▼ 0.59%Market cap $15.14MP/E —$3.21$65
- MDCXMedicus Pharma Ltd. Common Stock$3.25▼ 5.25%Market cap $16.97MP/E —$0.144$2.78
- HINDVyome Holdings Inc. Common Stock$1.87▼ 2.09%Market cap $15.02MP/E —$1.75$6.56
- KTTAPasithea Therapeutics Corp. Common Stock$0.42▲ 2.44%Market cap $14.82MP/E —$0.281$2.06
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| BFRI Biofrontera Inc. Common Stock | $16.00M | — | $0.822 | ▼ 2.95% | $0.555$1.66 |
| SKYE Skye Bioscience Inc. Common Stock | $16.58M | — | $1.55 | ▼ 2.52% | $1.5$13.28 |
| CYCN Cyclerion Therapeutics Inc. Common Stock | $16.67M | — | $3.36 | ▼ 0.15% | $7.19$59.36 |
| SCNX Scienture Holdings Inc. Common Stock | $15.14M | — | $3.36 | ▼ 0.59% | $3.21$65 |
| MDCX Medicus Pharma Ltd. Common Stock | $16.97M | — | $3.25 | ▼ 5.25% | $0.144$2.78 |
| HIND Vyome Holdings Inc. Common Stock | $15.02M | — | $1.87 | ▼ 2.09% | $1.75$6.56 |
| KTTA Pasithea Therapeutics Corp. Common Stock | $14.82M | — | $0.42 | ▲ 2.44% | $0.281$2.06 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Biofrontera Refiles Supplemental New Drug Application For Ameluz Topical Gel To FDA To Treat Actinic Keratosesbenzinga · 10/8/2026
- Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light PDT to Actinic Keratoses on the Full BodyYahoo · 10/8/2026
- Biofrontera Refiles Supplemental New Drug Application For Ameluz Topical Gel To FDA To Treat Actinic KeratosesBenzinga · 10/8/2026
- 12 Health Care Stocks Moving In Monday's After-Market SessionBenzinga · 10/5/2026
- Transcript: Biofrontera Q2 2026 Earnings Conference CallBenzinga · 9/28/2026
- Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell CarcinomaYahoo · 9/14/2026
- Biofrontera Receives FDA Supplemental New Drug Application Approval For Its Ameluz Topical Gel, 10%, In Combination With Photodynamic Therapy Using The BF-RhodoLED Lamp Series For The Treatment Of Superficial Basal Cell Carcinoma In AdultsBenzinga · 9/14/2026
Insider Activity
Insider Actions →- Hermann Luebbert · July 28, 2026 · Option Exercise62.5K
- Eugene Frederick Leffler · July 28, 2026 · Option Exercise31.3K
Institutional Ownership
March 31, 2026
- Total shares held
- 2.33M
- Total value held
- $1.89M
- Institutional holders
- 11
- Unknown1.16M
- Unknown915.2K
- Unknown109.3K
- Unknown52.3K
- Unknown38.6K
- Unknown22.5K
- Unknown11.8K
- Unknown10.2K
- Unknown4.6K
- Unknown1.5K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Biofrontera Q2 2026 Earnings Call Discusses Results
Biofrontera held its Q2 2026 earnings conference call, where management discussed the quarter's results and future plans. The call was broadcast on Benzinga and provided updates on revenue, expenses, and guidance. The stock is trading near the lower end of its 52‑week range and close to the $1.05 support level, which may influence short‑term market reactions.
Biofrontera Q2 2026 Earnings Call Discusses Results. Biofrontera held its Q2 2026 earnings conference call, where management discussed the quarter's results and future plans. The call was broadcast on Benzinga and provided updates on revenue, expenses, and guidance. The stock is trading near the lower end of its 52‑week range and close to the $1.05 support level, which may influence short‑term market reactions.